ADARx Pharmaceuticals filed its S-1 on September 21 targeting an IPO at $15–17 per share to raise up to $372 million, implying a post-IPO valuation near $1.74 billion at the midpoint and listing expected around September 25 under ticker ADRX. This siRNA biotech’s pipeline, led by Phase 3 onvuzosiran for hereditary angioedema plus mid-stage renal and complement programs, benefits from a substantial AbbVie collaboration that delivered a $335 million upfront payment in 2025 plus potential multi-billion milestones. Strong cash reserves and a concurrent AbbVie private placement for roughly 4.9% stake provide a solid floor, yet trader-implied odds remain dispersed across sub-$1.5 billion to $3 billion+ brackets because first-day closing market cap hinges on IPO demand, biotech sector sentiment, and any pricing adjustments amid the broader fall 2026 IPO window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$2.5B-$3B 24%
$1.5B-$1.75B 23%
<$1.5B 14%
No IPO before November 2026 14%
NEW
NEW
Sep 25, 2026
<$1.5B
14%
$1.5B-$1.75B
23%
$1.75B-$2B
12%
$2B-$2.25B
12%
$2.25B-$2.5B
12%
$2.5B-$3B
24%
$3B+
13%
No IPO before November 2026
14%
$2.5B-$3B 24%
$1.5B-$1.75B 23%
<$1.5B 14%
No IPO before November 2026 14%
NEW
NEW
Sep 25, 2026
<$1.5B
$0 Vol.
14%
$1.5B-$1.75B
$40 Vol.
23%
$1.75B-$2B
$0 Vol.
12%
$2B-$2.25B
$0 Vol.
12%
$2.25B-$2.5B
$0 Vol.
12%
$2.5B-$3B
$0 Vol.
24%
$3B+
$0 Vol.
13%
No IPO before November 2026
$0 Vol.
14%
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals filed its S-1 on September 21 targeting an IPO at $15–17 per share to raise up to $372 million, implying a post-IPO valuation near $1.74 billion at the midpoint and listing expected around September 25 under ticker ADRX. This siRNA biotech’s pipeline, led by Phase 3 onvuzosiran for hereditary angioedema plus mid-stage renal and complement programs, benefits from a substantial AbbVie collaboration that delivered a $335 million upfront payment in 2025 plus potential multi-billion milestones. Strong cash reserves and a concurrent AbbVie private placement for roughly 4.9% stake provide a solid floor, yet trader-implied odds remain dispersed across sub-$1.5 billion to $3 billion+ brackets because first-day closing market cap hinges on IPO demand, biotech sector sentiment, and any pricing adjustments amid the broader fall 2026 IPO window.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Market Opened: Sep 23, 2026, 6:43 PM ET
Volume
$40End Date
Sep 25, 2026Market Opened
Sep 23, 2026, 6:43 PM ETResolver
0x69c47de9d...This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.ADARx Pharmaceuticals filed its S-1 on September 21 targeting an IPO at $15–17 per share to raise up to $372 million, implying a post-IPO valuation near $1.74 billion at the midpoint and listing expected around September 25 under ticker ADRX. This siRNA biotech’s pipeline, led by Phase 3 onvuzosiran for hereditary angioedema plus mid-stage renal and complement programs, benefits from a substantial AbbVie collaboration that delivered a $335 million upfront payment in 2025 plus potential multi-billion milestones. Strong cash reserves and a concurrent AbbVie private placement for roughly 4.9% stake provide a solid floor, yet trader-implied odds remain dispersed across sub-$1.5 billion to $3 billion+ brackets because first-day closing market cap hinges on IPO demand, biotech sector sentiment, and any pricing adjustments amid the broader fall 2026 IPO window.
This market will resolve based on ADARx's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on September 24 (ET). If no such IPO occurs by October 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before November 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$40End Date
Sep 25, 2026Market Opened
Sep 23, 2026, 6:43 PM ETResolver
0x69c47de9d...ADARx Pharmaceuticals filed its S-1 on September 21 targeting an IPO at $15–17 per share to raise up to $372 million, implying a post-IPO valuation near $1.74 billion at the midpoint and listing expected around September 25 under ticker ADRX. This siRNA biotech’s pipeline, led by Phase 3 onvuzosiran for hereditary angioedema plus mid-stage renal and complement programs, benefits from a substantial AbbVie collaboration that delivered a $335 million upfront payment in 2025 plus potential multi-billion milestones. Strong cash reserves and a concurrent AbbVie private placement for roughly 4.9% stake provide a solid floor, yet trader-implied odds remain dispersed across sub-$1.5 billion to $3 billion+ brackets because first-day closing market cap hinges on IPO demand, biotech sector sentiment, and any pricing adjustments amid the broader fall 2026 IPO window.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions